BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The company plans to submit an Investigational New Drug (IND) application by mid-2025, with first Phase 1 single ascending dose (SAD) data expected by year-end.

A scientist in a lab coat analyzing samples from a petri dish, studying the effects of a potential drug candidate.

BGE-102, an internally discovered compound, is distinguished by its novel binding site, high potency, and brain penetration. In preclinical obesity models, BGE-102 delivered dose-dependent weight loss comparable to leading GLP-1 agonist semaglutide, achieving up to 15% reduction as monotherapy and over 20% when combined with semaglutide. The drug also improved insulin sensitivity and demonstrated a robust safety margin in toxicology studies.

BioAge Labs, Inc. (NASDAQ:BIOA)’s CEO, Kristen Fortney, Ph.D., highlighted BGE-102’s potential as a once-daily oral therapy, either alone or with GLP-1 receptor agonists, by targeting the NLRP3 inflammasome, a key driver of inflammation and metabolic dysfunction in obesity.

Pending IND clearance, BioAge Labs, Inc. (NASDAQ:BIOA) will launch Phase 1 trials, with a Phase 1b proof-of-concept study in obesity planned for late 2026.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.